Home › Ovarian Cancer › Pennsylvania
Ovarian Cancer clinical trials in Pennsylvania
69 studies for Ovarian Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- and 18 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- IRMC Cancer Center, Indiana
- UPMC Hillman Cancer Center - New Castle, New Castle
- and 2 more
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0232 - University of Pennsylvania, Philadelphia
- Site 0178 - Thomas Jefferson University, Philadelphia
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- University of Pennsylvania, Philadelphia
Recruiting
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05287451A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- St. Lukes University Hospital /ID# 274362, Bethlehem
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Philadelphia
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia
- Western Pennsylvania Gynecologic Oncology /ID# 278632, Pittsburgh
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Pennsylvania Hospital, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791Prehabilitation in High-risk Oncologic Surgery
- Fox Chase Cancer Center - Philadelphia, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07638410BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04752826A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Hospital of the University of Pennsylvania ( Site 0071), Philadelphia
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Penn State College of Medicine, Hershey
RecruitingPhase 2
Ages 18 to 99 · Women · Updated Sep 15, 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
- Allegheny Health Network- West Penn Hospital, Pittsburgh
- Lankenau Medical Center, Wynnewood
- and 1 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Allegheny Singer, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06303505Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- St. Luke's University Health Network, Bethlehem
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh
- West Penn Hospital of Allegheny Health Network, Pittsburgh
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- AHN West Penn Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07001748A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
- ACPMP, Springfield
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT07769346A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0109, Philadelphia
- Site 0113, Philadelphia
- Site 0114, Willow Grove
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 12, 2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Jefferson Abington Hospital, Abington
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Penn State Milton S Hershey Medical Center, Hershey
- and 15 more
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Saint Luke's Cancer Center - Allentown, Allentown
- Saint Luke's University Hospital-Bethlehem Campus, Bethlehem
- and 21 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.